Syndax Pharmaceuticals, Inc. Net Income (Loss) Available to Common Stockholders, Basic
Syndax Pharmaceuticals, Inc. (SNDX) reported Net Income (Loss) Available to Common Stockholders, Basic of -$49.36 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Income Statement › Net Income
us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic · last filed 2026-08-04
- Syndax Pharmaceuticals, Inc. net income (loss) available to common stockholders, basic for the quarter ending 2026-06-30 was -$49.36M.
- Syndax Pharmaceuticals, Inc. net income (loss) available to common stockholders, basic for the quarter ending 2026-03-31 was -$42.67M.
- Syndax Pharmaceuticals, Inc. net income (loss) available to common stockholders, basic for the quarter ending 2025-12-31 was -$68.01M.
- Syndax Pharmaceuticals, Inc. net income (loss) available to common stockholders, basic for the quarter ending 2025-09-30 was -$60.72M.
- Syndax Pharmaceuticals, Inc. net income (loss) available to common stockholders, basic for fiscal 2025 was -$285.42M.
- Syndax Pharmaceuticals, Inc. net income (loss) available to common stockholders, basic for fiscal 2024 was -$318.76M.
- Syndax Pharmaceuticals, Inc. net income (loss) available to common stockholders, basic for fiscal 2023 was -$209.36M.
- Syndax Pharmaceuticals, Inc. net income (loss) available to common stockholders, basic for fiscal 2022 was -$149.34M, a 699.13% decline from fiscal 2021.
| Period end | Net Income (Loss) Available to Common Stockholders, Basic 3 month | Net Income (Loss) Available to Common Stockholders, Basic 6 month | Net Income (Loss) Available to Common Stockholders, Basic 9 month | Net Income (Loss) Available to Common Stockholders, Basic 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$49.36M 10-Q · filed 2026-08-04 | -$92.04M 10-Q · filed 2026-08-04 | -$160.05M derived: sum of 3 quarters · filed 2026-08-04 | -$220.76M derived: sum of 4 quarters · filed 2026-08-04 |
| 2026-03-31 | -$42.67M 10-Q · filed 2026-04-30 | -$110.69M derived: sum of 2 quarters · filed 2026-04-30 | -$171.40M derived: sum of 3 quarters · filed 2026-04-30 | -$243.25M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-12-31 | -$68.01M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$128.73M derived: sum of 2 quarters · filed 2026-02-26 | -$200.58M derived: sum of 3 quarters · filed 2026-08-04 | -$285.42M 10-K · filed 2026-02-26 |
| 2025-09-30 | -$60.72M 10-Q · filed 2025-11-03 | -$132.56M derived: sum of 2 quarters · filed 2026-08-04 | -$217.41M 10-Q · filed 2025-11-03 | -$311.58M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-06-30 | -$71.85M 10-Q · filed 2026-08-04 | -$156.69M 10-Q · filed 2026-08-04 | -$250.86M derived: sum of 3 quarters · filed 2026-08-04 | -$334.99M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-03-31 | -$84.85M 10-Q · filed 2026-04-30 | -$179.01M derived: sum of 2 quarters · filed 2026-04-30 | -$263.14M derived: sum of 3 quarters · filed 2026-04-30 | -$331.20M derived: sum of 4 quarters · filed 2026-04-30 |
| 2024-12-31 | -$94.17M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$178.29M derived: sum of 2 quarters · filed 2026-02-26 | -$246.36M derived: sum of 3 quarters · filed 2026-02-26 | -$318.76M 10-K · filed 2026-02-26 |
| 2024-09-30 | -$84.13M 10-Q · filed 2025-11-03 | -$152.19M derived: sum of 2 quarters · filed 2025-11-03 | -$224.59M 10-Q · filed 2025-11-03 | -$297.06M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-06-30 | -$68.06M 10-Q · filed 2025-08-04 | -$140.46M 10-Q · filed 2025-08-04 | -$212.94M derived: sum of 3 quarters · filed 2026-02-26 | -$264.08M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-03-31 | -$72.40M 10-Q · filed 2025-05-05 | -$144.87M derived: sum of 2 quarters · filed 2026-02-26 | -$196.02M derived: sum of 3 quarters · filed 2026-02-26 | -$240.63M derived: sum of 4 quarters · filed 2026-02-26 |
| 2023-12-31 | -$72.47M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$123.62M derived: sum of 2 quarters · filed 2026-02-26 | -$168.23M derived: sum of 3 quarters · filed 2026-02-26 | -$209.36M 10-K · filed 2026-02-26 |
| 2023-09-30 | -$51.15M 10-Q · filed 2024-11-05 | -$95.76M derived: sum of 2 quarters · filed 2024-11-05 | -$136.89M 10-Q · filed 2024-11-05 | -$176.08M derived: sum of 4 quarters · filed 2025-03-03 |
| 2023-06-30 | -$44.62M 10-Q · filed 2024-08-01 | -$85.74M 10-Q · filed 2024-08-01 | -$124.94M derived: sum of 3 quarters · filed 2025-03-03 | -$160.34M derived: sum of 4 quarters · filed 2025-03-03 |
| 2023-03-31 | -$41.13M 10-Q · filed 2024-05-08 | -$80.32M derived: sum of 2 quarters · filed 2025-03-03 | -$115.72M derived: sum of 3 quarters · filed 2025-03-03 | -$153.29M derived: sum of 4 quarters · filed 2025-03-03 |
| 2022-12-31 | -$39.19M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-03 | -$74.60M derived: sum of 2 quarters · filed 2025-03-03 | -$112.17M derived: sum of 3 quarters · filed 2025-03-03 | -$149.34M 10-K · filed 2025-03-03 |
| 2022-09-30 | -$35.40M 10-Q · filed 2023-11-02 | -$72.97M derived: sum of 2 quarters · filed 2023-11-02 | -$110.14M 10-Q · filed 2023-11-02 | -$13.95M derived: sum of 4 quarters · filed 2024-02-27 |
| 2022-06-30 | -$37.57M 10-Q · filed 2023-08-03 | -$74.74M 10-Q · filed 2023-08-03 | $21.46M derived: sum of 3 quarters · filed 2024-02-27 | $818.00K derived: sum of 4 quarters · filed 2024-02-27 |
| 2022-03-31 | -$37.17M 10-Q · filed 2023-05-08 | $59.03M derived: sum of 2 quarters · filed 2024-02-27 | $38.39M derived: sum of 3 quarters · filed 2024-02-27 | $15.48M derived: sum of 4 quarters · filed 2024-02-27 |
| 2021-12-31 | $96.20M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | $75.56M derived: sum of 2 quarters · filed 2024-02-27 | $52.65M derived: sum of 3 quarters · filed 2024-02-27 | $24.93M 10-K · filed 2024-02-27 |
| 2021-09-30 | -$20.64M 10-Q · filed 2022-11-03 | -$43.55M derived: sum of 2 quarters · filed 2022-11-03 | -$71.27M 10-Q · filed 2022-11-03 | -$91.69M derived: sum of 4 quarters · filed 2022-11-03 |
| 2021-06-30 | -$22.91M 10-Q · filed 2022-08-08 | -$50.63M 10-Q · filed 2022-08-08 | -$71.06M derived: sum of 3 quarters · filed 2022-08-08 | -$91.49M derived: sum of 4 quarters · filed 2022-08-08 |
| 2021-03-31 | -$27.72M 10-Q · filed 2022-05-09 | -$48.15M derived: sum of 2 quarters · filed 2022-05-09 | -$68.58M derived: sum of 3 quarters · filed 2022-05-09 | -$85.64M derived: sum of 4 quarters · filed 2022-05-09 |
| 2020-12-31 | -$20.42M 10-K · filed 2021-03-12 | -$40.86M derived: sum of 2 quarters · filed 2021-11-15 | -$57.92M derived: sum of 3 quarters · filed 2021-11-15 | -$77.06M 10-K · filed 2023-02-28 |
| 2020-09-30 | -$20.44M 10-Q · filed 2021-11-15 | -$37.50M derived: sum of 2 quarters · filed 2021-11-15 | -$56.64M 10-Q · filed 2021-11-15 | -$70.64M derived: sum of 4 quarters · filed 2022-03-01 |
| 2020-06-30 | -$17.06M 10-Q · filed 2021-08-09 | -$36.20M 10-Q · filed 2021-08-09 | -$50.20M derived: sum of 3 quarters · filed 2022-03-01 | -$63.03M derived: sum of 4 quarters · filed 2022-03-01 |
| 2020-03-31 | -$19.14M 10-Q · filed 2021-05-11 | -$33.14M derived: sum of 2 quarters · filed 2022-03-01 | -$45.97M derived: sum of 3 quarters · filed 2022-03-01 | -$60.89M derived: sum of 4 quarters · filed 2022-03-01 |
| 2019-12-31 | -$14.00M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | -$26.83M derived: sum of 2 quarters · filed 2022-03-01 | -$41.74M derived: sum of 3 quarters · filed 2022-03-01 | -$56.05M 10-K · filed 2022-03-01 |
| 2019-09-30 | -$12.83M 10-Q · filed 2020-11-05 | -$27.75M derived: sum of 2 quarters · filed 2020-11-05 | -$42.05M 10-Q · filed 2020-11-05 | -$60.88M derived: sum of 4 quarters · filed 2021-03-12 |
| 2019-06-30 | -$14.92M 10-Q · filed 2020-08-06 | -$29.22M 10-Q · filed 2020-08-06 | -$48.05M derived: sum of 3 quarters · filed 2021-03-12 | -$65.39M derived: sum of 4 quarters · filed 2021-03-12 |
| 2019-03-31 | -$14.30M 10-Q · filed 2020-05-07 | -$33.14M derived: sum of 2 quarters · filed 2021-03-12 | -$50.48M derived: sum of 3 quarters · filed 2021-03-12 | -$68.86M derived: sum of 4 quarters · filed 2021-03-12 |
| 2018-12-31 | -$18.84M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-12 | -$36.17M derived: sum of 2 quarters · filed 2021-03-12 | -$54.56M derived: sum of 3 quarters · filed 2021-03-12 | -$73.96M 10-K · filed 2021-03-12 |
| 2018-09-30 | -$17.34M 10-Q · filed 2019-11-07 | -$35.73M derived: sum of 2 quarters · filed 2019-11-07 | -$55.12M 10-Q · filed 2019-11-07 | -$74.23M derived: sum of 4 quarters · filed 2020-03-05 |
| 2018-06-30 | -$18.39M 10-Q · filed 2019-08-07 | -$37.78M 10-Q · filed 2019-08-07 | -$56.89M derived: sum of 3 quarters · filed 2020-03-05 | -$71.98M derived: sum of 4 quarters · filed 2020-03-05 |
| 2018-03-31 | -$19.40M 10-Q · filed 2019-05-08 | -$38.50M derived: sum of 2 quarters · filed 2020-03-05 | -$53.59M derived: sum of 3 quarters · filed 2020-03-05 | -$67.23M derived: sum of 4 quarters · filed 2020-03-05 |
| 2017-12-31 | -$19.10M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-05 | -$34.19M derived: sum of 2 quarters · filed 2020-03-05 | -$47.83M derived: sum of 3 quarters · filed 2020-03-05 | -$60.80M 10-K · filed 2020-03-05 |
| 2017-09-30 | -$15.09M 10-Q · filed 2018-11-05 | -$28.73M derived: sum of 2 quarters · filed 2018-11-05 | -$41.70M 10-Q · filed 2018-11-05 | -$52.51M derived: sum of 4 quarters · filed 2019-03-07 |
| 2017-06-30 | -$13.64M 10-Q · filed 2018-08-08 | -$26.61M 10-Q · filed 2018-08-08 | -$37.42M derived: sum of 3 quarters · filed 2019-03-07 | -$52.39M derived: sum of 4 quarters · filed 2019-03-07 |
| 2017-03-31 | -$12.97M 10-Q · filed 2018-05-09 | -$23.79M derived: sum of 2 quarters · filed 2019-03-07 | -$38.76M derived: sum of 3 quarters · filed 2019-03-07 | -$47.11M derived: sum of 4 quarters · filed 2019-03-07 |
| 2016-12-31 | -$10.81M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-07 | -$25.78M derived: sum of 2 quarters · filed 2019-03-07 | -$34.14M derived: sum of 3 quarters · filed 2019-03-07 | -$47.07M 10-K · filed 2019-03-07 |
| 2016-09-30 | -$14.97M 10-Q · filed 2017-11-08 | -$23.33M derived: sum of 2 quarters · filed 2017-11-08 | -$36.26M 10-Q · filed 2017-11-08 | -$45.03M derived: sum of 4 quarters · filed 2018-03-08 |
| 2016-06-30 | -$8.36M 10-Q · filed 2017-08-10 | -$21.29M 10-Q · filed 2017-08-10 | -$30.07M derived: sum of 3 quarters · filed 2018-03-08 | -$86.72M derived: sum of 4 quarters · filed 2018-03-08 |
| 2016-03-31 | -$12.93M 10-Q · filed 2017-05-09 | -$21.71M derived: sum of 2 quarters · filed 2018-03-08 | -$78.36M derived: sum of 3 quarters · filed 2018-03-08 | -$104.70M derived: sum of 4 quarters · filed 2018-03-08 |
| 2015-12-31 | -$8.78M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-08 | -$65.44M derived: sum of 2 quarters · filed 2018-03-08 | -$91.77M derived: sum of 3 quarters · filed 2018-03-08 | -$103.84M 10-K · filed 2018-03-08 |
| 2015-09-30 | -$56.66M 10-Q · filed 2016-11-14 | -$82.99M derived: sum of 2 quarters · filed 2016-11-14 | -$95.07M 10-Q · filed 2016-11-14 | |
| 2015-06-30 | -$26.34M 10-Q · filed 2016-08-15 | -$38.41M 10-Q · filed 2016-08-15 | ||
| 2015-03-31 | -$12.07M 10-Q · filed 2016-05-16 | |||
| 2014-12-31 | -$26.36M 10-K · filed 2017-03-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |